Open Outbreak

Respiratory syncytial virus

Also known as: RSV, Human respiratory syncytial virus, hRSV, Human orthopneumovirus

Respiratory syncytial virus (RSV) is a common virus that infects the airways and lungs. It spreads between people through infectious respiratory particles in the air, and can also spread through direct contact or contaminated surfaces. Almost all children are infected by their second birthday. Infection does not give lasting protection, so people can catch RSV again. Most infections are mild, but RSV can cause serious breathing problems in young infants, older adults and people with underlying illnesses. Infants under six months are particularly vulnerable. Severe disease may require hospital care, fluids and oxygen. WHO reports that RSV causes approximately 3.6 million hospitalizations and 100,000 deaths each year among children under five worldwide; these are annual burden estimates, not counts for 2026. Vaccines for eligible adults and vaccination during pregnancy are available. Long-acting antibody injections can also protect infants. Availability and eligibility differ between countries. The sources reviewed do not establish the current worldwide RSV situation as of 2026-11-22.

Key facts

TransmissionPerson-to-person through infectious respiratory particles in the air; direct contact and contaminated surfaces are also thought to transmit RSV.
IncubationSymptoms usually begin 4–7 days after exposure, according to WHO.
Case fatalityUnknown from the reviewed sources. No overall case-fatality percentage or treated-versus-untreated comparison is provided; annual death estimates are not case-fatality rates.
Reproduction numberUnknown from the reviewed sources; no RSV-specific R0 or secondary attack-rate estimate was retrieved.
VaccineWHO lists a maternal vaccine to protect infants and three licensed vaccines for older adults and adults with certain underlying illnesses. Two long-acting monoclonal antibody products are also licensed for infant prevention; these are not vaccines. Local eligibility and availability vary.
TreatmentWHO describes no specific treatment. Severe disease is managed with supportive care, including clearing nasal secretions, fluids and supplemental oxygen.
ReservoirHumans; WHO describes RSV as specific to humans.
Endemic regionsWorldwide, with seasonal epidemics in temperate climates and locally varying periods of increased circulation in tropical and subtropical regions.

Transmission

RSV spreads from an infected person to another person through infectious respiratory particles in the air. WHO also identifies direct contact with infected people and contact with contaminated surfaces as possible routes. Human-to-human transmission is therefore an ordinary feature of RSV, not a new warning sign. Almost all babies have been infected by their second birthday. Older children and adults can become infected again, usually with mild illness, although older adults and people with important underlying conditions can become seriously ill. Symptoms generally begin 4–7 days after exposure. The sources reviewed do not provide an RSV-specific reproduction number or secondary attack rate, so this page does not assign a numerical estimate of contagiousness.

Symptoms and severity

RSV can cause a runny nose, sore throat, headache, tiredness and fever. Some young children do not have fever. When infection reaches the lower airways and lungs, symptoms can include cough, shortness of breath, fast breathing and wheezing. Severe illness can lower oxygen levels and exhaust the muscles used for breathing. Infants under six months, older adults and people with underlying illnesses are at greatest risk. In older adults, RSV can worsen existing heart or lung disease. WHO estimates approximately 3.6 million hospitalizations and 100,000 deaths annually among children under five worldwide. These are estimates of disease burden, not the likelihood that an individual infection will be fatal. The reviewed sources do not provide a general case-fatality rate or a comparison between treated and untreated patients.

Treatment and vaccines

WHO describes treatment as supportive care rather than a specific cure for RSV. Hospital care for severe illness may include clearing nasal secretions, giving fluids and, most importantly, providing oxygen. Prevention has expanded substantially. A vaccine given during pregnancy allows protective antibodies to pass to the baby before birth. WHO recommends vaccination in the third trimester, defined from 28 weeks in most settings, and describes protection lasting approximately six months after birth. Long-acting antibody injections offer another way to protect infants; these supply antibodies directly and are not vaccines. WHO lists two licensed infant antibody products and three vaccines for older adults and adults with certain underlying illnesses. Recommendations, access and product availability depend on the country. These preventive products do not replace care for an infant or adult who is already seriously ill.

Where it occurs

RSV occurs worldwide rather than being confined to a particular outbreak region. Most countries have periods of increased circulation each year. In temperate climates, epidemics tend to occur in late autumn and winter. Tropical and subtropical countries also experience recurring periods of higher activity, but their timing is less uniform. Local surveillance is therefore more useful than assuming that every country follows the same season. The burden of severe childhood disease is uneven: WHO reports that 97% of paediatric RSV deaths occur in low- and middle-income countries, where access to supportive medical care is limited. That figure describes the distribution of deaths, not the distribution of all infections. WHO also notes that global estimates of adult RSV disease burden are not known.

Recent history

As of 2026-11-22, this site's archive contains zero RSV events, and the archive tool returned no records. That reflects the archive's coverage, not an absence of RSV epidemics. A WHO notice dated 2025-01-07 discussed RSV alongside influenza and other respiratory infections in the Northern Hemisphere. It reported rising RSV activity in North America but decreases in several other monitored regions. Data from China through 2024-12-29 showed increases in common respiratory infections within the expected seasonal range; WHO had received no reports of unusual outbreak patterns there. These findings describe that earlier reporting period, not November 2026. Another important recent development is the introduction of maternal vaccination, adult vaccines and long-acting infant antibodies, documented in the retrieved literature and WHO fact sheet.

What to watch

The most useful warning signals are increases in severe illness and pressure on hospitals, not simply the detection of RSV. Watch for activity outside a region's usual season, unusually large rises in admissions, and simultaneous circulation of several respiratory viruses. WHO notes that these overlapping epidemics can burden health services. Because RSV already circulates worldwide and spreads between people, a new location report or ordinary household transmission does not by itself indicate a new threat. Access to prevention also matters: shortages or poor access to vaccines and infant antibodies could leave vulnerable groups less protected. Reports that preventive products are becoming less effective would warrant investigation, but the reviewed sources do not establish such a resistance trend. For an individual, shortness of breath or fast breathing warrants prompt medical assessment.

Updated